Filed under: Investment Strategy
What P/E (PER) Really Means in Today’s Market
When you look at the U.S. markets these days, it’s easy to feel a sense of "valuation fatigue." AI stocks look expensive, and semiconductors seem to have hit a local ceiling. Naturally, investors start searching for the "cheap" entries.
The first metric many reach for is the P/E (Price-to-Earnings) ratio, often referred to as PER in Korea. P/E answers a foundational question: At today’s share price, how many years of current earnings would it take to “earn back” the price?
The formula is simple:
p/e = price / EPS
The key is comparing P/E within the same industry. Tech often trades at 30–40x multiples because expectations are sky-high, while financials or legacy manufacturers may trade closer to 10x. But a low P/E is rarely a "free lunch." If expectations are low, there’s usually a reason. Today, we’ll look at one low-P/E name in three different sectors, why the market is discounting them, and what could trigger a reversal.
1. Tech: HP Inc. (NYSE: HPQ)
Current P/E: 7.92
HPQ is a cornerstone of the PC and printer industry. While PC sales provide the bulk of their volume, the printer supplies business (the "consumables" model) acts as a steady cash cow.
Why the P/E is low
The market discount is straightforward:
Mature Business: HP is seen as a legacy player with a weaker growth narrative compared to software-as-a-service (SaaS) or AI firms.
Cyclicality: PC demand is highly sensitive to economic cycles. When budgets tighten, replacement cycles lengthen.
The "Paperless" Shadow: The printing segment lives under the long-term threat of a digital-only world.
Currently, the market doesn't award HPQ much "future" in its valuation. It is priced as a company that generates cash today but may struggle to find new growth engines.
Outlook
Unlike its rival Dell, which has successfully pivoted toward AI servers, HP has yet to show a similar infrastructure breakthrough. Realistically, HP’s path to upside is a multiple re-rating rather than explosive growth. The main catalyst? An AI PC replacement cycle that forces businesses to upgrade their hardware sooner than planned. Until then, HPQ remains a "cash-return" story, with a healthy 5.59% dividend yield doing the heavy lifting.
2. Financials: Allstate (NYSE: ALL)
Current P/E: 6.53
Allstate is a titan in the U.S. property and casualty insurance market. Insurance is fundamentally a game of probabilities: collect premiums, manage risk, and invest the "float."
Why the P/E is low
Insurers typically face discounts for two core reasons:
Catastrophe Risk: Markets fear massive, unpredictable losses from storms, wildfires, or hurricanes.
Regulatory Friction: Pricing power is often limited by state-level regulations, making it hard to pass costs to consumers quickly.
Allstate recently reported roughly $83 million in losses from wind and hail events in early October. While net income recently surged by 100.9%, the market is looking at the long game. Expected revenue growth for Allstate over the next three years is projected at around 4.3%, significantly lower than the broader U.S. market estimate of 10.4%.
Outlook
The path to improvement is clearer here than for HP. If catastrophe loss ratios normalize and the company continues its aggressive share repurchases, the P/E could expand. The upside isn't about "reinventing" insurance; it's about the market gaining confidence that profitability has reached a sustainable, "normal" level.
3. Healthcare: Solventum (NYSE: SOLV)
Current P/E: 9.32
Solventum is the healthcare business recently spun off from 3M. It focuses on recurring-use medical supplies used in hospitals and clinical settings—essentially the "picks and shovels" of healthcare.
Why the P/E is low
Spin-offs often trade at a deep discount in their first year (SOLV listed in March 2024) because:
Institutional Selling: Many former 3M shareholders sold their SOLV shares because they didn't fit their original investment mandate.
Legacy Baggage: Investors still mentally link SOLV to 3M’s historical legal and regulatory headaches.
Operational Reset: The company is still in the "intense" phase of restructuring its operations as a standalone entity.
Outlook
Solventum looks significantly undervalued compared to its high-multiple healthcare peers. CEO Bryan Hanson is currently "pruning" the company—selling off weak filtration segments and refocusing on core, high-margin products. If 2025 serves as the "reset" year, 2026 could be when the narrative shifts from an "uncertain spin-off" to a "focused healthcare leader."
Epilogue: The Value Investor’s Edge
Stock prices reflect expectations, and low P/E ratios are signs of skepticism.
HPQ faces growth skepticism.
ALL faces environmental and regulatory skepticism.
SOLV faces structural skepticism.
When hunting for value, don't just ask if a stock is cheap. Ask: "Why does the market refuse to pay more, and is that reason temporary?" The edge in value investing is catching the exact moment when the reason everyone disliked the stock finally gets resolved.
This post is for informational purposes only and does not constitute investment advice. Please consult with a financial professional before making any investment decisions.
Next reads:
Related Analysis
Explore More
Read the full guide
Comments
Post a Comment